Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,200 Cr revenue.
COGS 25.5%, employees 11.6%.
“We believe that this is just a timing difference and postponement of sales and not loss of business.”
“Excluding these initial start up costs, our Amrita margin stood at 41%.”
“6%. 76%.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 17.1%▲ | 10.5% |
| ROCE | 22.1%▲ | 13.8% |
| Net Margin | 25.9%▲ | 8.7% |
| EBITDA Margin | 40.0%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
| (₹ Cr) | TTM | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | ₹1,159 Cr -3.4% | ₹1,200 Cr +18.0% | ₹1,017 Cr |
| Other Income | ₹46 Cr +4.4% | ₹44 Cr +31.6% | ₹34 Cr |
| Total Income | ₹1,205 Cr -3.2% | ₹1,245 Cr +18.4% | ₹1,051 Cr |
| COGS | ₹288 Cr -5.6% | ₹306 Cr +33.3% | ₹229 Cr |
| ₹789 Cr +5.4% | ₹749 Cr +16.7% | ₹642 Cr | |
| Profit Before Tax | ₹413 Cr -16.8% | ₹496 Cr +21.2% | ₹409 Cr |
| Exceptional Items | (₹3 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| ₹103 Cr -16.2% | ₹123 Cr +17.7% | ₹104 Cr | |
| Net Profit | ₹311 Cr -16.3% | ₹372 Cr +20.6% | ₹308 Cr |
| Profit (Owners) | ₹313 Cr -15.9% | ₹372 Cr +20.6% | ₹308 Cr |
| Minority Interest | (₹1 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹49 Cr +728.6% | ₹6 Cr ↑ Recovery | (₹0.01 Cr) |
| EPS | ₹29.87 | ₹35.52 | ₹29.45 |
| Diluted Shares | ₹10 Cr | ₹10 Cr | ₹10 Cr |
| Profit Or Loss Of Associates | ₹2 Cr ↑ Recovery | (₹1 Cr) ↓ Decline | ₹3 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange regarding 'Completion of ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility'.
Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval for Tofacitinib Tablets, 5 mg and 10 mg
Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'.
Concord Biotech Limited has informed the Exchange about Investor Presentation
Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange regarding 'Updates'.
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange about Schedule of meet
Concord Biotech Limited has informed the Exchange about Transcript
Concord Biotech Limited has informed the Exchange about Link of Recording
Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication